Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorGonzalez, I. (Iranzu)-
dc.creatorViudez, A. (A.)-
dc.creatorGoñi, S. (Saioa)-
dc.creatorSantamaria, E. (Enrique)-
dc.creatorCarrasco-García, E. (Estefania)-
dc.creatorPérez-Sanz, J. (Jairo)-
dc.creatorHernández-García, I. (Irene)-
dc.creatorSala-Elarre, P. (Pablo)-
dc.creatorArrazubi, V. (Virginia)-
dc.creatorOyaga-Iriarte, E. (Esther)-
dc.creatorZarate, R. (Ruth)-
dc.creatorArévalo, S. (Sara)-
dc.creatorSayar, O. (Onintza)-
dc.creatorVera, R. (Ruth)-
dc.creatorFernandez-Irigoyen, J. (Joaquín)-
dc.date.accessioned2021-11-11T09:02:26Z-
dc.date.available2021-11-11T09:02:26Z-
dc.date.issued2019-
dc.identifier.citationGonzalez, I. (Iranzu); Viudez, A. (A.); Goñi, S. (Saioa); et al. "Omics approaches in pancreatic adenocarcinoma". Cancers. 11 (8), 2019, 1052es
dc.identifier.issn2072-6694-
dc.identifier.urihttps://hdl.handle.net/10171/62533-
dc.description.abstractPancreatic ductal adenocarcinoma, which represents 80% of pancreatic cancers, is mainly diagnosed when treatment with curative intent is not possible. Consequently, the overall five-year survival rate is extremely dismal—around 5% to 7%. In addition, pancreatic cancer is expected to become the second leading cause of cancer-related death by 2030. Therefore, advances in screening, prevention and treatment are urgently needed. Fortunately, a wide range of approaches could help shed light in this area. Beyond the use of cytological or histological samples focusing in diagnosis, a plethora of new approaches are currently being used for a deeper characterization of pancreatic ductal adenocarcinoma, including genetic, epigenetic, and/or proteo-transcriptomic techniques. Accordingly, the development of new analytical technologies using body fluids (blood, bile, urine, etc.) to analyze tumor derived molecules has become a priority in pancreatic ductal adenocarcinoma due to the hard accessibility to tumor samples. These types of technologies will lead us to improve the outcome of pancreatic ductal adenocarcinoma patients.es_ES
dc.description.sponsorshipThis work was funded by grants from Department of Health from Government of Navarra (Ref. 008-2018), REFBIO II Pyrenees Biomedical Network from Programa INTERREG V-A España-Francia-Andora (Ref. BMK_PANC) and Sociedad Española de Oncología Médica (SEOM) to A.V. I.G.-B. is supported by a predoctoral fellowship from Department of Economic Development Government of Navarre “Ayudas para la contratación de doctorandos y doctorandas por empresas y organismos de investigación y difusión de conocimientos: doctorados industriales 2018–2020”.es_ES
dc.language.isoenges_ES
dc.publisherMDPI AGes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectPancreatic adenocarcinomaes_ES
dc.subjectctDNAes_ES
dc.subjectProteomices_ES
dc.subjectGenomices_ES
dc.subjectMetabolomices_ES
dc.subjectLipidomices_ES
dc.subjectFFPEes_ES
dc.subjectTissuees_ES
dc.subjectBody fluidses_ES
dc.titleOmics approaches in pancreatic adenocarcinomaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.note© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.identifier.doi10.3390/cancers11081052-
dadun.citation.number8es_ES
dadun.citation.publicationNameCancerses_ES
dadun.citation.startingPage1052es_ES
dadun.citation.volume11es_ES

Ficheros en este ítem:
Vista previa
Fichero
cancers-11-01052-v2.pdf
Descripción
Tamaño
884.09 kB
Formato
Adobe PDF


Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.